通过超高灵敏度全身[18F]FDG PET/CT成像评估非小细胞肺癌患者的动态代谢异质性:原发肿瘤与转移性淋巴结中[18F]FDG摄取的定量分析
本研究纳入30例新诊断IIIA-IV期非小细胞肺癌患者,于治疗前行60分钟动态全身[18F]FDG PET/CT,基于原发肿瘤影像特征用无监督K-means聚类将患者分为快动态FDG代谢组(F-DFM)与慢动态FDG代谢组(S-DFM)。F-DFM组原发肿瘤Patlak-Ki(P < 0.001)与SUVmean(P < 0.001)显著高于S-DFM组,而两组转移性淋巴结的Patlak-Ki与SUVmean无显著差异;S-DFM组原发肿瘤FDG摄取异质性更高,F-DFM组原发肿瘤T细胞与巨噬细胞浸润更高。
要点
- 动态全身[18F]FDG PET/CT可基于原发肿瘤Patlak-Ki与SUVmean将NSCLC分为F-DFM与S-DFM两组。
- F-DFM组原发肿瘤Patlak-Ki与SUVmean显著高于S-DFM组,两组转移性淋巴结无显著差异。
- F-DFM组原发肿瘤T细胞与巨噬细胞浸润更高,提示可能从免疫治疗中获益。
核心结论
- 动态全身[18F]FDG PET/CT可基于原发肿瘤Patlak-Ki与SUVmean将NSCLC患者分为F-DFM与S-DFM两组。
- F-DFM组原发肿瘤在[18F]FDG摄取上似乎比S-DFM组更均匀。
- F-DFM组观察到更高的T细胞与巨噬细胞浸润,提示可能从免疫治疗中获益。
研究设计与样本
- 本研究于治疗前行60分钟动态全身[18F]FDG PET/CT,手动勾画原发肿瘤与转移性淋巴结。
- 采用无监督K-means分类方法基于原发肿瘤影像特征对患者进行聚类。
- 从原发肿瘤与转移性淋巴结提取Patlak-Ki、Patlak-Intercept、SUVmean、代谢肿瘤体积(MTV)、总病灶糖酵解(TLG)及纹理特征。
- 对肿瘤相关基因进行靶向下一代测序,并用免疫组化测定原发肿瘤中Ki67、CD3、CD8、CD34、CD68与CD163表达。
- 共纳入30例IIIA-IV期NSCLC患者。
主要发现
- F-DFM组原发肿瘤Patlak-Ki显著高于S-DFM组(P < 0.001)。
- F-DFM组原发肿瘤SUVmean显著高于S-DFM组(P < 0.001)。
- 两组转移性淋巴结的Patlak-Ki与SUVmean无显著差异。
- 纹理分析提示S-DFM组原发肿瘤FDG摄取较F-DFM组更不均匀。
- F-DFM组原发肿瘤T细胞(CD3+/CD8+)与巨噬细胞(CD68+/CD163+)浸润更高,两组肿瘤突变负荷无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to quantitatively assess [18F]FDG uptake in primary tumor (PT) and metastatic lymph node (mLN) in newly diagnosed non-small cell lung cancer (NSCLC) using the total-body [18F]FDG PET/CT and to characterize the dynamic metabolic heterogeneity of NSCLC. METHODS: The 60-min dynamic total-body [18F]FDG PET/CT was performed before treatment. The PTs and mLNs were manually delineated. An unsupervised K-means classification method was used to cluster patients based on the imaging features of PTs. The metabolic features, including Patlak-Ki, Patlak-Intercept, SUVmean, metabolic tumor volume (MTV), total lesion glycolysis (TLG), and textural features, were extracted from PTs and mLNs. The targeted next-generation sequencing of tumor-associated genes was performed. The expression of Ki67, CD3, CD8, CD34, CD68, and CD163 in PTs was determined by immunohistochemistry. RESULTS: A total of 30 patients with stage IIIA-IV NSCLC were enrolled. Patients were divided into fast dynamic FDG metabolic group (F-DFM) and slow dynamic FDG metabolic group (S-DFM) by the unsupervised K-means classification of PTs. The F-DFM group showed significantly higher Patlak-Ki (P < 0.001) and SUVmean (P < 0.001) of PTs compared with the S-DFM group, while no significant difference was observed in Patlak-Ki and SUVmean of mLNs between the two groups. The texture analysis indicated that PTs in the S-DFM group were more heterogeneous in FDG uptake than those in the F-DFM group. Higher T cells (CD3+/CD8+) and macrophages (CD68+/CD163+) infiltration in the PTs were observed in the F-DFM group. No significant difference was observed in tumor mutational burden between the two groups. CONCLUSION: The dynamic total-body [18F]FDG PET/CT stratified NSCLC patients into the F-DFM and S-DFM groups, based on Patlak-Ki and SUVmean of PTs. PTs in the F-DFM group seemed to be more homogenous in terms of [18F]FDG uptake than those in the S-DFM group. The higher infiltrations of T cells and macrophages were observed in the F-DFM group, which suggested a potential benefit from immunotherapy.
引用
- Wang D, Zhang X, Liu H, et al. Assessing dynamic metabolic heterogeneity in non-small cell lung cancer patients via ultra-high sensitivity total-body [18F]FDG PET/CT imaging: quantitative analysis of [18F]FDG uptake in primary tumors and metastatic lymph nodes. Eur J Nucl Med Mol Imaging. 2022. PMID: 35819498. doi:10.1007/s00259-022-05904-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。